Sorry, you need to enable JavaScript to visit this website.

Prevenar 13®

Prevenar 13®

Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) is indicated for:

  • Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks to 17 years of age.
  • Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.

The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.

Use our quick links to find out more information about Prevenar 13 in children and Prevenar 13 vaccine in adults

Current Recommendations in the UK

The Department of Health recommends Prevenar 13 for particular groups: 

  • The Prevenar 13 vaccine should be administered according to the schedule for the routine immunisation programme, at 8 weeks, 16 weeks and on their first birthday
  • For children under 10 years of age in any clinical risk group*
  • For children 10 years onwards and adults in a clinical risk group **
  • For children under the age of two with unknown or incomplete vaccination histories 

The British HIV Association (BHIVA) guidance recommends all adults who are HIV positive should receive a single dose Prevenar 13, irrespective of CD4 cell count, antiretroviral (ART) use or viral load.

*Asplenia or splenic dysfunction, chronic respiratory disease, chronic heart disease, chronic kidney disease, chronic liver disease, diabetes, immunosuppression, individual cochlear implants, individuals with cerebrospinal fluid leaks, bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement deficiency).

** Bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement deficiency)

For an in depth pneumococcal immunisation schedule for individuals in a clinical risk group please visit chapter 25 of the green book:

The safety of Prevenar 13® was assessed in controlled clinical studies and the safety profile of Prevenar 13® was similar to Prevenar®.

For Prevenar 13® the most commonly reported adverse reactions in children 6 weeks to 5 years of age were vaccination-site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep.

 Reports of all adverse reactions can be found in the summary of product characteristics for Prevenar 13® available at https://www.medicines.org.uk.